Market Size and Forecast Market Size in 2025: USD 60.6 Billion Market Size by 2035: USD 307 Billion CAGR: 17.61% from 2026 to 2035 Base Year: 2025 Forecast Period: 2026-2035 Historical Data: 2022-2024 To Get more information on GLP-1 Receptor Agonist Market - Request Free Sample Report GLP-1 Receptor Agonist Market Trends Oral GLP-1 formulations led by Novo Nordisk's Rybelsus and Eli Lilly's orforglipron in development are expanding the patient population who will accept GLP-1 therapy by removing the injection barrier that constrains current market penetration
Nothing in the patients health history indicated that hed been infected with the bacterium that causes tuberculosis, Mycobacterium tuberculosis (Mtb)
However, even then, the work done (populating fields) can be saved or printed out to send, reducing the burden
Geburtshilfe Frauenheilkd
Although Novo Nordisk and Eli Lily, the maker of Mounjaro, another GLP-1 drug, wanted to have cases moved to other jurisdictions, such as North Carolina or California, the MDL Panel declined because a significant amount of the pending lawsuits (at least 13 out of 55) are already filed in the Eastern District of Pennsylvania which is close to Novo Nordisks New Jersey headquarters
It supports long-term weight management and can improve weight-related health conditions
